Celltrion

Asthma inhaler
#Celltrion

Omlyclo set to become commercially available in Europe

The drug Omlyclo, the first and only omalizumab biosimilar in Europe, will be commercially available in the European market, biopharmaceutical company Celltrion has announced.  Omlyclo, a drug used to treat chronic spontaneous urticaria (CSU), allergic asthma and chronic rhinosinusitis with nasal polyps, will be available in Norway… Read More

#News

US Food and Drug Administration
#Biologics / Biotechnology #Celltrion #Crohn's disease #FDA #Inflammatory Bowel Disease #Phase III trial #United States

First subcutaneous formulation of infliximab submitted to FDA

Celltrion USA has submitted a Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act for CT-P13 SC for the treatment of inflammatory bowel disease (IBD).  The submission is based on results from the Phase III pivotal data that evaluated the efficacy and safety of… Read More

#News #Regulatory